Roman Sergeevich Knyazev
Direktor/Vorstandsmitglied bei PHARMSYNTHEZ
Profil
Roman Sergeevich Knyazev is currently a Director at Pharmsynthez PJSC, Nanolek Holding Ltd., and Tsentr PETAR LLC.
He previously held positions as a Non-Executive Director at Xenetic Biosciences (UK) Ltd.
and Xenetic Biosciences, Inc., an Investment Director at Rusnano OJSC and Rusnano Management Co. LLC, and a Director at Lipoxen Technologies Ltd.
and SynBio LLC.
Knyazev received an undergraduate degree from Moscow State University Lomonosov.
Aktive Positionen von Roman Sergeevich Knyazev
Unternehmen | Position | Beginn |
---|---|---|
PHARMSYNTHEZ | Direktor/Vorstandsmitglied | 20.02.2013 |
Nanolek Holding Ltd.
Nanolek Holding Ltd. BiotechnologyHealth Technology Nanolek Holding Ltd. operates as a holding Cypriot company that provides biotechnological services. | Direktor/Vorstandsmitglied | 01.01.2013 |
Tsentr PETAR LLC | Direktor/Vorstandsmitglied | 01.01.2012 |
Ehemalige bekannte Positionen von Roman Sergeevich Knyazev
Unternehmen | Position | Ende |
---|---|---|
XENETIC BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 25.09.2019 |
Rusnano OJSC
Rusnano OJSC Miscellaneous Commercial ServicesCommercial Services Rusnano OJSC operates as an investment company focusing on nanotechnology. Its activities include building nanotechnology infrastructure, which includes the nanotechnology centers of excellence, business incubators and early stage investment funds; It also provides scientific and educational programs. The company was founded on September 19, 2007 and is headquartered in Moscow, Russian Federation. | Chief Investment Officer | 01.01.2014 |
Xenetic Biosciences (UK) Ltd.
Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Direktor/Vorstandsmitglied | 01.01.2013 |
Rusnano Management Co. LLC
Rusnano Management Co. LLC Investment ManagersFinance Rusnano Management Co. LLC (Rusnano Management) is a private equity and venture capital subsidiary of the State-owned Rusnano OJSC. The firm was founded in 2013 and is headquartered in Moscow, Russia. | Chief Investment Officer | - |
Lipoxen Technologies Ltd.
Lipoxen Technologies Ltd. Pharmaceuticals: MajorHealth Technology Founded in 1997, Lipoxen Technologies Ltd. is a British company that specializes in product development in the pharmaceutical industry. Part of Xenetic Biosciences, Inc., the company is based in London, UK. | Direktor/Vorstandsmitglied | - |
Ausbildung von Roman Sergeevich Knyazev
Moscow State University Lomonosov | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
PHARMSYNTHEZ | Health Technology |
XENETIC BIOSCIENCES, INC. | Health Technology |
Private Unternehmen | 7 |
---|---|
SynBio LLC
SynBio LLC Pharmaceuticals: MajorHealth Technology SynBio LLC engages in original research and introduction of conceptually new medicines. The firm’s medicines help treat diseases like liver disease, cardiovascular disease, acute leukemia, growth hormone deficiency and diabetes milletus. Its work is based on scientific developments and conducted in cutting edge laboratories. The company was founded in 2011 and is headquartered in Moscow, Russian Federation. | Health Technology |
Xenetic Biosciences (UK) Ltd.
Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Health Technology |
Rusnano OJSC
Rusnano OJSC Miscellaneous Commercial ServicesCommercial Services Rusnano OJSC operates as an investment company focusing on nanotechnology. Its activities include building nanotechnology infrastructure, which includes the nanotechnology centers of excellence, business incubators and early stage investment funds; It also provides scientific and educational programs. The company was founded on September 19, 2007 and is headquartered in Moscow, Russian Federation. | Commercial Services |
Nanolek Holding Ltd.
Nanolek Holding Ltd. BiotechnologyHealth Technology Nanolek Holding Ltd. operates as a holding Cypriot company that provides biotechnological services. | Health Technology |
Lipoxen Technologies Ltd.
Lipoxen Technologies Ltd. Pharmaceuticals: MajorHealth Technology Founded in 1997, Lipoxen Technologies Ltd. is a British company that specializes in product development in the pharmaceutical industry. Part of Xenetic Biosciences, Inc., the company is based in London, UK. | Health Technology |
Rusnano Management Co. LLC
Rusnano Management Co. LLC Investment ManagersFinance Rusnano Management Co. LLC (Rusnano Management) is a private equity and venture capital subsidiary of the State-owned Rusnano OJSC. The firm was founded in 2013 and is headquartered in Moscow, Russia. | Finance |
Tsentr PETAR LLC |